Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
CNTX
Context Therapeutics Inc.
CNTX is a biotech company focused on oncology therapeutics (solid tumors) leveraging immunotherapy approaches.
|
$144.42M |
$1.55
-3.13%
|
|
PLX
Protalix BioTherapeutics, Inc.
Protalix manufactures recombinant proteins/enzymes (e.g., Elelyso, Elfabrio) using its plant-based ProCellEx system.
|
$143.52M |
$1.82
+1.39%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 is Relmada's lead oncology candidate targeting non-muscle invasive bladder cancer (NMIBC).
|
$143.06M |
$4.30
-2.93%
|
|
JYNT
The Joint Corp.
The Joint operates chiropractic clinics delivering hands-on care, representing a healthcare services & facilities business.
|
$141.77M |
$9.25
+3.01%
|
|
AIRS
AirSculpt Technologies, Inc.
AirSculpt provides premium, minimally invasive body contouring services through a network of centers, i.e., healthcare services and facilities.
|
$141.11M |
$2.29
+3.38%
|
|
IMMX
Immix Biopharma, Inc.
Directly categorizes the company’s lead product as a CAR-T cell therapy (cell therapy).
|
$140.42M |
$4.85
-4.72%
|
|
XGN
Exagen Inc.
Exagen provides diagnostic testing services and operates lab facilities for autoimmune diagnostics.
|
$139.50M |
$6.12
-0.81%
|
|
RPID
Rapid Micro Biosystems, Inc.
Growth Direct is a diagnostic equipment platform for automated microbial detection used in pharmaceutical QC.
|
$138.38M |
$3.12
-3.85%
|
|
LNSR
LENSAR, Inc.
Direct ophthalmic device product (Ophthalmology Devices) produced by LENSAR via the ALLY robotic cataract laser system.
|
$138.09M |
$11.55
-1.03%
|
|
IXHL
Incannex Healthcare Limited
Incannex develops oral small-molecule therapeutics as fixed-dose drug combinations (IHL-42X).
|
$137.69M |
$0.40
|
|
ANIK
Anika Therapeutics, Inc.
Company develops and sells orthopedic devices including implants for cartilage repair and related regenerative solutions.
|
$137.26M |
$9.52
-0.31%
|
|
MCRB
Seres Therapeutics, Inc.
SER-155 is a cultivated live biotherapeutic product (cell therapy) comprising a defined bacterial consortium.
|
$137.01M |
$15.63
+1.17%
|
|
EDAP
Edap Tms S.a.
Focal One is a robotic surgical energy delivery device used for focal therapy of urological cancers.
|
$136.92M |
$3.65
-3.69%
|
|
STIM
Neuronetics, Inc.
NeuroStar Advanced Therapy System is a non-invasive neuromodulation device; the direct product of the company.
|
$136.88M |
$2.09
+6.63%
|
|
PDEX
Pro-Dex, Inc.
Direct product: the company manufactures surgical instruments (autoclavable, battery-powered multi-function handpieces and shavers).
|
$136.16M |
$41.35
+0.12%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is Tonix's lead oral small-molecule drug for fibromyalgia (cyclobenzaprine HCl sublingual), a direct product the company develops and plans to bring to market.
|
$135.70M |
$15.38
+1.38%
|
|
ACTU
Actuate Therapeutics Inc
Actuate Therapeutics is a biotech company focused on oncology with a lead product elraglusib (a GSK-3β inhibitor).
|
$134.64M |
$6.27
-3.39%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$134.08M |
$3.37
+3.06%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$133.66M |
$0.44
-1.51%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$131.69M |
$8.12
-1.52%
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$131.50M |
$2.35
-0.42%
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$130.56M |
$2.33
-0.64%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is a recombinant humanized IgG2 monoclonal antibody targeting soluble AßOs.
|
$129.63M |
$2.15
+9.69%
|
|
NIKA
Nika Pharmaceuticals Inc.
ITV-1 HIV therapeutic concept and related immunomodulatory platform sit within Biotech - Immunology Therapeutics.
|
$129.43M |
$0.38
|
|
FBIO
Fortress Biotech, Inc.
Fortress Biotech directly encompasses oncology-focused biotech through its portfolio (e.g., Mustang Bio) and related assets, aligning with Biotech - Oncology.
|
$127.95M |
$4.37
-0.23%
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$127.80M |
$1.72
+2.69%
|
|
BTMD
biote Corp.
Vertical pellet therapy and related implantable products can be categorized under Medical Devices & Biometrics.
|
$127.55M |
$2.60
+2.96%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Core antibody discovery platform offering de novo antibody design and epitope mapping via LENSai/HYFT.
|
$125.54M |
N/A
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$124.61M |
$0.76
-1.85%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$124.59M |
$3.94
+4.93%
|
|
ATRA
Atara Biotherapeutics, Inc.
Company operates in oncology with cell-based immunotherapies (tab-cel).
|
$123.46M |
$17.70
+0.71%
|
Showing page 24 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
